Resource Summary Report

Generated by SPARC SAWG on Aug 10, 2026

FITC anti-human CD19

RRID:AB_314236
Type: Antibody

Proper Citation

BioLegend Cat# 302206, RRID:AB_314236

Antibody Information

URL: http://antibodyregistry.org/AB_314236

Proper Citation: BioLegend Cat# 302206, RRID:AB_314236

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_314236

Vendor: BioLegend

Catalog Number: 302206

Alternative Catalog Numbers: 302205, 302256

Record Creation Time: 20250819T221949+0000

Record Last Update: 20250820T015100+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD19.

No alerts have been found for FITC anti-human CD19.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Wang Q, et al. (2026) Human monoclonal antibodies that target the SFTSV glycoprotein Gn head from four neutralizing epitope groups. Cell reports, 45(4), 117248.

Bennstein SB, et al. (2026) A single-cell transcriptional reference for the functional and developmental diversity of neonatal innate lymphoid cells. Cell reports, 45(3), 117000.

Zhao Y, et al. (2026) Natural killer cell dysfunction drives keloid pathogenesis. Cell reports, 45(4), 117129.

Jiang W, et al. (2026) Basophil activity in atopic dermatitis: Distinct immunomodulatory roles of dupilumab and abrocitinib. The Journal of investigative dermatology.

Wang W, et al. (2025) Potent human antibodies against SpA5 identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells. iScience, 28(1), 111627.

Mitsuno K, et al. (2025) Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer immunology, immunotherapy : CII, 74(3), 79.

Tang M, et al. (2025) Single cell immune profiling in ankylosing spondylitis reveals resistance of CD8+ T cells to immune exhaustion. iScience, 28(7), 112715.

Hu J, et al. (2025) CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. Cell reports, 44(10), 116351.

Sirenko M, et al. (2025) Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell stem cell, 32(7), 1102.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V?9V?2 T cell cytotoxicity against autologous and cancer cells. Cell reports, 44(10), 116387.

Hegelmaier T, et al. (2025) Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. Med (New York, N.Y.), 6(9), 100776.

Krapi? M, et al. (2025) NK cell-derived IFN? mobilizes free fatty acids from adipose tissue to promote early B cell activation during viral infection. Nature metabolism, 7(5), 985.

Ni Y, et al. (2024) Human yolk sac-derived innate lymphoid-biased multipotent progenitors emerge prior to hematopoietic stem cell formation. Developmental cell, 59(19), 2626.

Liang Z, et al. (2024) Intestinal CXCR6+ ILC3s migrate to the kidney and exacerbate renal fibrosis via IL-23 receptor signaling enhanced by PD-1 expression. Immunity, 57(6), 1306.

Liu C, et al. (2024) Protocol for in vitro generation of innate lymphoid cells from human embryonic tissues. STAR protocols, 6(1), 103525.

MacDonald L, et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, 57(12), 2843.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-?1 and IL-2 confer immunoregulatory functions to NK cells. iScience, 27(12), 111416.

Sun J, et al. (2024) Metabolic regulator LKB1 controls adipose tissue ILC2 PD-1 expression and mitochondrial homeostasis to prevent insulin resistance. Immunity, 57(6), 1289.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.